By Spondylitis Association of America
A phase 4 clinical trial is now recruiting patients over the age of 18 with active ankylosing spondylitis (AS) to participate in a study evaluating the clinical difference between 300 mg and 150 mg of secukinumab.
As an integral component of its mission and ongoing commitment to fund research for a cure for spondyloarthritis (SpA), the Spondylitis Association of America (SAA) is pleased to announce the recipients of its 2018 SAA/Bruckel Early Career Investigator Award in AxSpA and additional grants for funding exploratory research.
Fibromyalgia (FM) is a relatively well-known musculoskeletal disorder characterized by widespread pain, fatigue, and sleep issues. However, few are aware of its comorbidities. The frequent pain and other symptoms normally associated with FM can be further exacerbated when occurring along with ankylosing spondylitis, axial spondyloarthritis (axSpA),psoriatic arthritis (PsA) or rheumatoid arthritis (RA). A
On April 28, 2018 the Spondylitis Association of America hosted a free Spondylitis Educational Seminar in Denver, CO. Our speakers for the day were Rheumatologist Liron Caplan, MD PhD and Clinical Health Psychologist Jana Bolduan Lomax, PsyD.
Previously, there has been no conclusive data that has demonstrated a consistent pattern of disease activity in pregnant women with axial spondyloarthritis (axSpA.) A recent study out of Norway sought to come to a definitive conclusion using proven scientific methods, such as the BASDAI, BASFAI and CRP.
Visit our careers page for available positions
16360 Roscoe Blvd. Ste. 100Van Nuys, CA 91406
(800) 777-8189 U.S. only
or (818) 892-1616*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.